Tolerance, Danger, and the Extended Family, Annual Review of Immunology, vol.12, issue.1, pp.991-1045, 1994. ,
DOI : 10.1146/annurev.iy.12.040194.005015
Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-52, 1998. ,
DOI : 10.1038/32588
Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses, Current Opinion in Immunology, vol.23, issue.1, pp.10-20, 2011. ,
DOI : 10.1016/j.coi.2010.12.015
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination, Nature Reviews Immunology, vol.8, issue.7, pp.479-91, 2012. ,
DOI : 10.1038/nri3247
Nucleic Acid Recognition by the Innate Immune System, Annual Review of Immunology, vol.29, issue.1, pp.185-214, 2011. ,
DOI : 10.1146/annurev-immunol-031210-101340
Accessory molecules for Toll-like receptors and their function, Nature Reviews Immunology, vol.268, issue.3, pp.168-79, 2012. ,
DOI : 10.1038/nri3151
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677579
Adjuvants for cancer vaccines, Seminars in Immunology, vol.22, issue.3, pp.155-61, 2010. ,
DOI : 10.1016/j.smim.2010.04.007
Dendritic cell vaccination and immune monitoring, Cancer Immunology, Immunotherapy, vol.183, issue.Suppl 1, pp.1559-68, 2008. ,
DOI : 10.1007/s00262-008-0553-y
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491428
Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies, Expert Review of Vaccines, vol.12, issue.3, pp.285-95, 2013. ,
DOI : 10.1586/erv.13.22
Cancer immunotherapy via dendritic cells, Nature Reviews Cancer, vol.29, issue.4, pp.265-77, 2012. ,
DOI : 10.1038/nrc3258
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433802
Dendritic cells in cancer immunotherapy, European Journal of Immunology, vol.111, issue.8, pp.2123-2153, 2010. ,
DOI : 10.1002/eji.201040630
Development of TLR9 agonists for cancer therapy, Journal of Clinical Investigation, vol.117, issue.5, pp.1184-94, 2007. ,
DOI : 10.1172/JCI31414
HUMAN T CELL RESPONSES AGAINST MELANOMA, Annual Review of Immunology, vol.24, issue.1, pp.175-208, 2006. ,
DOI : 10.1146/annurev.immunol.24.021605.090733
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen, Proceedings of the National Academy of Sciences, vol.105, issue.10, pp.3849-54, 2008. ,
DOI : 10.1073/pnas.0800080105
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268830
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma, The Journal of Immunology, vol.175, issue.9, pp.6169-76, 2005. ,
DOI : 10.4049/jimmunol.175.9.6169
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death, Nature, vol.131, issue.7029, pp.88-93, 2005. ,
DOI : 10.1074/jbc.M208167200
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides, Clinical Cancer Research, vol.18, issue.23, pp.6485-96, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-1516
Therapeutic cancer vaccines, Journal of Clinical Investigation, vol.125, issue.9, pp.3401-3413, 2015. ,
DOI : 10.1172/JCI80009
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588240
Cancer despite immunosurveillance: immunoselection and immunosubversion, Nature Reviews Immunology, vol.65, issue.10, pp.715-742, 2006. ,
DOI : 10.1038/nri1936
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, Journal of Clinical Oncology, vol.32, issue.10, pp.1020-1050, 2014. ,
DOI : 10.1200/JCO.2013.53.0105
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117
DNA Vaccines: Immunology, Application, and Optimization, Annual Review of Immunology, vol.18, issue.1, pp.927-74, 2000. ,
DOI : 10.1146/annurev.immunol.18.1.927
A Novel Toll-Like Receptor that Recognizes Bacterial DNA, Nature, vol.408, issue.6813, pp.740-745, 2000. ,
DOI : 10.1385/1-59259-305-4:039
Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity, Immunological Reviews, vol.160, issue.1, pp.251-69, 2007. ,
DOI : 10.1073/pnas.231606698
The role of toll-like receptors in systemic autoimmune disease, International Congress Series, vol.1285, issue.11, pp.823-858, 2006. ,
DOI : 10.1016/j.ics.2005.07.101
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling, Nature, vol.80, issue.7213, pp.674-682, 2008. ,
DOI : 10.1038/nature07317
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804933
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity, Nature, vol.80, issue.7265, pp.788-92, 2009. ,
DOI : 10.1038/nature08476
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664154
STING: infection, inflammation and cancer, Nature Reviews Immunology, vol.900, issue.12, pp.760-70, 2015. ,
DOI : 10.1371/journal.pone.0077846
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004891
The interferon response to intracellular DNA: Why so many receptors?, Immunobiology, vol.218, issue.11, pp.1312-1333, 2013. ,
DOI : 10.1016/j.imbio.2013.07.007
Regulation and function of the cGAS???STING pathway of cytosolic DNA sensing, Nature Immunology, vol.17, issue.10, pp.1142-1151, 2016. ,
DOI : 10.1038/nature18268
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway, Science, vol.339, issue.6121, pp.786-91, 2013. ,
DOI : 10.1126/science.1232458
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA, Science, vol.339, issue.6121, pp.826-856, 2013. ,
DOI : 10.1126/science.1229963
Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-??B Activation through TBK1, Journal of Virology, vol.88, issue.10, pp.5328-5369, 2014. ,
DOI : 10.1128/JVI.00037-14
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019140
DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking, Proceedings of the National Academy of Sciences, vol.110, issue.8, pp.2969-74, 2013. ,
DOI : 10.1073/pnas.1222694110
Immune Sensing of DNA, Immunity, vol.38, issue.5, pp.870-80, 2013. ,
DOI : 10.1016/j.immuni.2013.05.004
Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease, Current Opinion in Immunology, vol.31, pp.121-127, 2014. ,
DOI : 10.1016/j.coi.2014.10.009
Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA, European Journal of Immunology, vol.8, issue.10, pp.2847-53, 2014. ,
DOI : 10.1002/eji.201344407
Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses, The Journal of Immunology, vol.191, issue.7, pp.3509-3522, 2013. ,
DOI : 10.4049/jimmunol.1301419
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation, Cancer Research, vol.76, issue.8, pp.2076-81, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-1456
Inflammation-driven carcinogenesis is mediated through STING, Nature Communications, vol.2013, p.5166, 2014. ,
DOI : 10.1126/science.1211600
URL : http://doi.org/10.1038/ncomms6166
A critical function for type I interferons in cancer immunoediting, Nature Immunology, vol.92, issue.7, pp.722-731, 2005. ,
DOI : 10.1146/annurev.immunol.21.120601 .141007
Type I interferon is selectively required by dendritic cells for immune rejection of tumors, The Journal of Experimental Medicine, vol.134, issue.10, pp.1989-2003, 2011. ,
DOI : 10.4049/jimmunol.0803214
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors, Immunity, vol.41, issue.5, pp.830-872, 2014. ,
DOI : 10.1016/j.immuni.2014.10.017
ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization, Proceedings of the National Academy of Sciences, vol.106, issue.21, pp.8653-8661, 2009. ,
DOI : 10.1073/pnas.0900850106
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689030
The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation, Immunity, vol.29, issue.4, pp.538-50, 2008. ,
DOI : 10.1016/j.immuni.2008.09.003
MPYS, a Novel Membrane Tetraspanner, Is Associated with Major Histocompatibility Complex Class II and Mediates Transduction of Apoptotic Signals, Molecular and Cellular Biology, vol.28, issue.16, pp.5014-5040, 2008. ,
DOI : 10.1128/MCB.00640-08
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity, Proceedings of the National Academy of Sciences, vol.112, issue.50, pp.15408-15421, 2015. ,
DOI : 10.1073/pnas.1512832112
dendritic cells, The Journal of Experimental Medicine, vol.61, issue.10, pp.2005-2021, 2011. ,
DOI : 10.1158/0008-5472.CAN-07-5324
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors, Immunity, vol.41, issue.5, pp.843-52, 2014. ,
DOI : 10.1016/j.immuni.2014.10.019
STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells, The Journal of Immunology, vol.193, issue.12, pp.6124-6158, 2014. ,
DOI : 10.4049/jimmunol.1401869
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258444
STING manifests self DNA-dependent inflammatory disease, Proceedings of the National Academy of Sciences, vol.109, issue.47, pp.19386-91, 2012. ,
DOI : 10.1073/pnas.1215006109
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511090
STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment, Cancer Immunology Research, vol.2, issue.12, pp.1199-208, 2014. ,
DOI : 10.1158/2326-6066.CIR-14-0099
MyD88 and its divergent toll in carcinogenesis, Trends in Immunology, vol.34, issue.8, pp.379-89, 2013. ,
DOI : 10.1016/j.it.2013.03.008
Cutting Edge: STING Mediates Protection against Colorectal Tumorigenesis by Governing the Magnitude of Intestinal Inflammation, The Journal of Immunology, vol.193, issue.10, pp.4779-82, 2014. ,
DOI : 10.4049/jimmunol.1402051
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, vol.10, issue.7423, pp.259-63, 2012. ,
DOI : 10.1038/nature11535
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18, The Journal of Experimental Medicine, vol.62, issue.8, pp.1625-1661, 2010. ,
DOI : 10.1016/j.ajhg.2008.03.016
Diverse roles of STING-dependent signaling on the development of cancer, Oncogene, vol.34, issue.41, pp.5302-5310, 2015. ,
DOI : 10.1016/j.cell.2011.04.022
The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity, Cancer Research, vol.71, issue.7, pp.2488-96, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-2820
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer, Clinical Cancer Research, vol.21, issue.21, pp.4774-4783, 2015. ,
DOI : 10.1158/1078-0432.CCR-15-1362
DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway, Science, vol.350, issue.6260, pp.568-71, 2015. ,
DOI : 10.1126/science.aab3291
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis, Cell Reports, vol.14, issue.2, pp.282-97, 2016. ,
DOI : 10.1016/j.celrep.2015.12.029
RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma, Cancer Research, vol.74, issue.8, pp.2193-203, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-1703
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor, Nature, vol.19, issue.7054, pp.1186-90, 2005. ,
DOI : 10.1038/nature03884
The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells, Immunity, vol.44, issue.5, pp.1177-89, 2016. ,
DOI : 10.1016/j.immuni.2016.04.010
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice, Cancer Treat Rep, vol.70, issue.5, pp.631-636, 1986. ,
Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours, Cancer Chemotherapy and Pharmacology, vol.140, issue.5, pp.269-72, 1989. ,
DOI : 10.1007/BF00304756
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours, Cancer Chemotherapy and Pharmacology, vol.87, issue.5, pp.661-670, 2007. ,
DOI : 10.1007/s00280-006-0321-7
Immunomodulatory Actions of Xanthenone Anticancer Agents, BioDrugs, vol.8, issue.2, pp.119-146, 1997. ,
DOI : 10.2165/00063030-199708020-00005
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.29, issue.22, pp.2965-71, 2011. ,
DOI : 10.1200/JCO.2011.35.0660
5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential, Journal of Biological Chemistry, vol.287, issue.47, pp.39776-88, 2012. ,
DOI : 10.1074/jbc.M112.382986
Structure-Function Analysis of STING Activation by c[G(2???,5???)pA(3???,5???)p] and Targeting by Antiviral DMXAA, Cell, vol.154, issue.4, pp.748-62, 2013. ,
DOI : 10.1016/j.cell.2013.07.023
Anticancer Flavonoids Are Mouse-Selective STING Agonists, ACS Chemical Biology, vol.8, issue.7, pp.1396-401, 2013. ,
DOI : 10.1021/cb400264n
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815523
Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid, The Journal of Immunology, vol.190, issue.10, pp.5216-5241, 2013. ,
DOI : 10.4049/jimmunol.1300097
STING is a direct innate immune sensor of cyclic di-GMP, Nature, vol.6, issue.7370, pp.515-523, 2011. ,
DOI : 10.1038/nature10429
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer, Cancer Immunology Research, vol.2, issue.9, pp.901-911, 2014. ,
DOI : 10.1158/2326-6066.CIR-13-0123
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264585
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice, Cancer Immunology, Immunotherapy, vol.169, issue.8, pp.1057-66, 2015. ,
DOI : 10.1007/s00262-015-1713-5
Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides, PLoS ONE, vol.28, issue.10, p.77846, 2013. ,
DOI : 10.1371/journal.pone.0077846.s002
The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STING, Cell Reports, vol.3, issue.5, pp.1355-61, 2013. ,
DOI : 10.1016/j.celrep.2013.05.009
Cyclic [G(2???,5???)pA(3???,5???)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase, Cell, vol.153, issue.5, pp.1094-107, 2013. ,
DOI : 10.1016/j.cell.2013.04.046
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response, Scientific Reports, vol.3, issue.1, 2016. ,
DOI : 10.1002/0471142735.im0307s86
STING Recognition of Cytoplasmic DNA Instigates Cellular Defense, Molecular Cell, vol.50, issue.1, pp.5-15, 2013. ,
DOI : 10.1016/j.molcel.2013.01.039
The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response, Nature Immunology, vol.13, issue.12, pp.1155-61, 2012. ,
DOI : 10.1038/nm1246
Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING, Molecular Cell, vol.51, issue.2, pp.226-261, 2013. ,
DOI : 10.1016/j.molcel.2013.05.022
URL : http://doi.org/10.1016/j.molcel.2013.05.022
Hydrolysis of 2???3???-cGAMP by ENPP1 and design of nonhydrolyzable analogs, Nature Chemical Biology, vol.10, issue.12, pp.1043-1051, 2014. ,
DOI : 10.1359/jbmr.070714
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity, Cell Reports, vol.11, issue.7, pp.1018-1048, 2015. ,
DOI : 10.1016/j.celrep.2015.04.031
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Science Translational Medicine, vol.7, issue.283, pp.283-52, 2015. ,
DOI : 10.1126/scitranslmed.aaa4306
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504692
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade, Cancer Immunology Research, vol.4, issue.12, pp.1061-1071, 2016. ,
DOI : 10.1158/2326-6066.CIR-16-0104
T cell phenotypes in cancer, OncoImmunology, vol.123, issue.4, p.998538, 2015. ,
DOI : 10.1038/84701
TH9 cells in anti-tumor immunity, Semin Immunopathol, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01416031
The immune contexture in human tumours: impact on clinical outcome, Nature Reviews Cancer, vol.29, issue.4, pp.298-306, 2012. ,
DOI : 10.1038/nrc3245
Stimulator of interferon genes (STING): A ???new chapter??? in virus-associated cancer research. Lessons from wild-derived mouse models of innate immunity, Cytokine & Growth Factor Reviews, vol.29, pp.83-91, 2016. ,
DOI : 10.1016/j.cytogfr.2016.02.009
IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV, Science, vol.343, issue.6169, pp.428-460, 2014. ,
DOI : 10.1126/science.1243640
T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication, PLoS ONE, vol.14, issue.1, p.84513, 2014. ,
DOI : 10.1371/journal.pone.0084513.s006